Sentiment Summary
Recent Events
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
Cochlear's full-year financial results for fiscal year 2026 are scheduled to be announced on August 18, 2026. Medium importance is estimated as annual earnings reports typically result in price movements exceeding 5%, scheduled.
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
Medtronic to report Q4 and full fiscal year 2026 financial results, scheduled.
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
Q1 2026 earnings release scheduled. Analysts forecast revenue of 7.52B HKD. Estimated Medium importance as earnings results typically drive significant price movement scheduled.
Publication of full-year results for the 2025/26 financial year, with growth expected at the lower end of guided ranges (5%-9% sales, 14%-18% EBITA) and High importance estimated due to expected >10% volatility following a strategic shift, scheduled.
The ex-dividend date for the Q2 2026 dividend of $1.73 per share, payable on June 10, 2026.
Announced a share repurchase plan for A-shares with a total amount of RMB 500 million to RMB 1 billion, at a price not exceeding RMB 60.00 per share, announced on May 13, 2026. The shares will be used for employee incentives or cancellation. This large-scale buyback is estimated to have a price impact of ≥5%.
Received clinical trial approval from China's NMPA for HS-10541 tablets on 2026-05-13; estimated 5% impact due to innovative drug pipeline expansion.
The company is expected to receive Investigational New Drug (IND) approval from China's NMPA for SKB118; this pipeline milestone is estimated to have a 5% price impact as it validates the drug's potential expected.
Leerink Partners upgraded Johnson & Johnson stock to 'Outperform' from 'Market Perform' and raised its price target to $265 from $252, citing promising growth forecasts for new products Icotyde and Inlexzo; price impact estimated at 5% due to positive analyst sentiment forecasted.
Announced the global launch of the next-generation Shockwave C2 Aero coronary intravascular lithotripsy (IVL) catheter on 2026-05-13; price impact estimated at 5% due to market expansion expected.
Repurchased 1.78 million shares for approximately HKD 10.05 million on 2026-05-13. This is estimated to have a price impact of ≥1% expected.
Subsidiary Fosun Pharma Industrial to sign an exclusive option agreement with AriBio for global licensing rights to Alzheimer's candidate AR1001; the strategic expansion is estimated to have a 1-5% price impact, expected.
AIDS Healthcare Foundation filed a lawsuit against Alphabet on 2026-05-13. This is estimated to have a Low (>=1%) impact as legal challenges are frequent for tech giants and rarely result in immediate significant price movement.
Global strategic collaboration and licensing agreement with Bristol-Myers Squibb (BMS) for 13 early-stage programs in oncology, hematology, and immunology, with a potential value of up to $15.2 billion and upfront/near-term payments of $950 million; the high deal value is estimated to result in a price impact exceeding 10%, scheduled
Controlling shareholders, Chairman Mr. Ye Xiaoping and Director Ms. Cao Xiaochun, received a case filing notice from the China Securities Regulatory Commission (CSRC) on May 12, 2026, for an investigation into suspected violations regarding information disclosure of historical shareholding changes. This regulatory action against top management is estimated to have a price impact of ≥10%.
Alphabet announced 'Googlebook' and 'Gemini Intelligence' on 2026-05-12. This major strategic AI push is estimated to have a High (>=10%) impact on market sentiment regarding the company's future hardware ecosystem.
Eli Lilly announced positive late-stage trial results showing patients maintained long-term weight loss by switching from high-dose injectable GLP-1s to lower-dose Zepbound or the oral pill Foundayo (orforglipron).
Executive President and Global Chief Medical Officer, Yongjiang Hei, was reported to have officially resigned to start his own venture. Estimated Low importance as executive changes in large firms often have limited immediate price impact.
Announced an exclusive strategic collaboration with GSK to commercialize bepirovirsen in mainland China on 2026-05-11; analysts forecast high sales potential and a price impact of ≥10% forecasted.
On May 11, 2026, the company reported Q1 2026 financial results with revenue of $26.5M (+29% YoY), but a wider-than-expected loss per share of $0.52, missing the consensus estimate of -$0.39. The net loss widened to $19.7M from $12.8M in the prior year, attributed to increased operating and litigation costs. The company raised its full-year 2026 revenue guidance. The high importance is justified by the significant earnings miss and rising legal expenses likely to impact the stock by over 10%.
Announced that its ADC drug SYS6010 was granted another Breakthrough Therapy Designation in China for treating esophageal squamous cell carcinoma. Estimated Low importance as breakthrough designations are positive but early-stage regulatory milestones.
IBI363 is expected to receive its third Breakthrough Therapy Designation from the NMPA on May 10, 2026; this clinical milestone's low market impact is expected
HS-20093 granted Breakthrough Therapy Designation by China's NMPA for esophageal squamous cell carcinoma on 2026-05-09; estimated 5% impact from accelerated approval path.
The U.S. FDA issued a Class I recall correction for certain ACCOLADE pacemakers on 2026-05-08 due to a software-related battery issue. High importance assigned due to potential for ≥10% price impact from safety concerns. Expected.
The NMPA is expected to approve the Mazdutide pen for type 2 diabetes on May 8, 2026; this core product approval's medium market impact is expected
The sNDA for sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab is expected to be accepted for review by China's NMPA; this regulatory progress is estimated to have a 5% price impact expected.
Reported Q1 2026 revenue of $759.9 million (+27% YoY) and non-GAAP EPS of $1.12 (+64.7% YoY), beating analyst estimates. The company also raised its full-year 2026 non-GAAP EPS guidance to $4.70-$4.80. Despite the strong results, the stock declined approximately 4.7% on the following trading day.